SIM
BMRN icon

SSI Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

SSI Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,149
Closed -$265K – 260
2020
Q2 		$265K Buy
+2,149
New +$214K 0.02% 225
2014
Q4 		– Sell
-3,750
Closed -$271K – 367
2014
Q3 		$271K Buy
+3,750
New +$246K 0.03% 323
2014
Q1 		– Sell
-4,953
Closed -$348K – 400
2013
Q4 		$348K Buy
+4,953
New +$336K 0.03% 362

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SSI Investment Management's BMRN Position: Q3 2020 in Review

SSI Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2020, closing a stake of 2,149 shares — an estimated $265K sold.

SSI Investment Management first reported a position in BMRN in Q4 2013 and held it in 3 quarters. The position peaked at $348K in Q4 2013. 496 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

  • SSI Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • SSI Investment Management sold 2,149 BioMarin Pharmaceuticals shares in Q3 2020, an estimated $265K.
  • SSI Investment Management first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 3 quarters.
  • SSI Investment Management's BioMarin Pharmaceuticals position peaked at $348K in Q4 2013.
  • 496 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on SSI Investment Management's 13F filing for Q3 2020, filed 16 Nov 2020.